HR Positive/HER-2 Negative Breast Cancer
Conditions
Brief summary
This is an open-label, single-arm phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of NTQ1062 in combination with Fulvestrant in patients with locally advanced or metastatic HR positive/HER-2 negative breast cancer.
Interventions
DRUGNTQ1062 with Fulvestrant
Drug: NTQ1062 tablet(s) ，PO，QD in cycles of 28 days (21 days on treatment followed by 7 days off treatment). Drug: Fulvestrant Injection 500mg in a 28-day cycle.
Sponsors
Nanjing Chia-tai Tianqing Pharmaceutical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Aged at least 18 years old at the time of informed consent. 2. Premenopausal, perimenopausal, or postmenopausal women. Premenopausal and perimenopausal women must receive ovarian function suppression therapy during the study, and are willing to receive continuous treatment during the study. 3. HR-positive or HER-2 negative breast cancer as histologically confirmed; metastatic or locally advanced disease that has recurred or progressed and for which, in the judgment of the investigator, curative surgery is not possible. 4. ECOG score is 0-1. 5. Predicted life expectancy ≥3 months. 6. Patients must have adequate organ function. 7. Patients must be signed written informed consent prior to admission to the study.
Exclusion criteria
1. Patients have received previous treatment with Fulvestrant or Akt inhibitors. 2. Patients who have received chemotherapy, biological therapy, immunotherapy, radiotherapy and other anti-tumor therapy or participated in other therapeutic clinical studies (except observational clinical studies) from 4 weeks prior to the first dose. 3. Treatment with systemic corticosteroids (prednisone \> 10 mg/day or equivalent) or other immunosuppressive agents for the treatment of non-neoplastic diseases within 14 days prior to the first dose. 4. Patients received strong inhibitors and/or inducers of CYP3A4 within 14 days or 5 drug half-lives prior to the first dose of study drug. 5. Patients who have undergone major surgical procedures or significant traumatic injuries within 4 weeks prior to the first administration (excluding minor surgeries such as appendicitis and tumor biopsy), or who require elective surgery during the trial period and are not suitable for clinical research. 6. Patients who have a history of receiving attenuated live vaccines or live vaccines within 4 weeks before the first administration, or who plan to receive such vaccines during the study period. 7. Patients who have received prior hematopoietic stem cell transplantation or organ transplantation. 8. The adverse reactions of previous anti-tumor therapy have not yet recovered to CTCAE 5.0 level evaluation ≤ 1 level. 9. Active or uncontrolled serious infection (≥ CTCAE Grade 2) or unexplained fever \> 38.5 ℃ within 28 days prior to first dose. 10. History of immunodeficiency, including positive HIV antibody test. 11. Patients with active hepatitis: those with positive hepatitis B B surface antigen (HBsAg) and more copies of HBV DNA than the positive value detected by the research center; Individuals who are positive for hepatitis C virus (HCV) antibodies and have tested positive for HCV RNA. 12. Syphilis screening positive Patients. 13. Previous medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or any evidence of clinically active interstitial lung disease. 14. History of serious cardiovascular and cerebrovascular diseases. 15. Refractory nausea and vomiting, malabsorption syndrome, ulcerative colitis, symptomatic/inflammatory bowel disease, chronic diarrhea and intestinal obstruction and other serious gastrointestinal diseases, inability to take oral swallowing drugs, or the presence of conditions that seriously affect gastrointestinal absorption as judged by the investigator. 16. Clinically uncontrolled third space effusion requiring repeated drainage or medical intervention (14 days prior to the first dose), which is not suitable based on the investigator's judgment. 17. Known alcohol or drug dependence. 18. Patients with mental disorders or poor compliance. 19. Previous history of severe allergies, or allergies to any active or inactive ingredients such as NTQ1062, Fluvastatin, and LHRH agonists (if applicable, LHRH agonists are required during this study period) 20. Pregnant or lactating women. 21. Other conditions that the investigator considers inappropriate for participation in this clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose (MTD) | First treatment cycle ( 28 days) | The MTD is defined as the highest dose reached for which the incidence of DLT occurs in less than 1/3 of the subjects. |
| Recommended phase 2 dose (RP2D) | Through study completion, an average of 1 year | RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data. |
| Adverse events | Through study completion, an average of 1 year | Safety and tolerability of NTQ1062 in combination with Fluvastatin. Incidence of adverse events. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic parameters: T1/2 | At the end of Cycle 3 (each cycle is 28 days) | The terminal half-life of NTQ1062 and NTQ1062-M. |
| Objective response rate (ORR) | Through study completion, an average of 1 year | ORR is defined as participants with confirmed complete or partial response. |
| Pharmacokinetic parameters: Cmax | At the end of Cycle 3 (each cycle is 28 days) | Maximum Serum Concentration (Cmax) of NTQ1062 and NTQ1062-M. |
| Duration of Response (DOR) | Through study completion, an average of 1 year | DOR is defined as the time between date of first response and the first occurrence. |
| Progression-free Survival (PFS) | Through study completion, an average of 1 year | PFS will be defined as the time between the first dose of any study drug and the first occurrence of progression or death from any cause. |
| Disease Control Rate (DCR) | Through study completion, an average of 1 year | DCR was defined as the proportion of patients who had an overall response of complete response (CR), partial response (PR), or stable disease (SD). |
| Pharmacokinetic parameters: Tmax | At the end of Cycle 3 (each cycle is 28 days) | Time to Maximum Serum Concentration (Cmax) of NTQ1062 and NTQ1062-M. |
| Pharmacokinetic parameters: AUC | At the end of Cycle 3 (each cycle is 28 days) | The area under the concentration versus time curve of NTQ1062 and NTQ1062-M. |
Countries
China
Contacts
Primary ContactYu meng Zhou
Outcome results
None listed